News Category
PolyPeptide shareholders approved a new board and the removal of transfer restrictions, clearing key conditions for Samsung Biologics' tender offer.
VERAXA Biotech's adoption of FDA-aligned New Approach Methodologies could significantly reduce animal testing and accelerate the development of its ne...
Peptide Wholesale Supply has expanded its HPLC verification protocols to bulk orders of BPC-157, Semaglutide, and Tirzepatide, providing batch-specifi...
Telomir Pharmaceuticals' Telomir-Zn demonstrated growth inhibition in human and canine osteosarcoma cell lines, supporting further studies that could ...
Kairos Pharma's CEO presentation at a major investment conference underscores the company's progress in developing ENV-105, an antibody aimed at rever...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials marks a significant milestone for a novel myelin-repair approach to multiple...
Nutriband receives USPTO Notice of Publication for trademarks related to its abuse-deterrent fentanyl patch, moving closer to commercialization of a p...
Quantum BioPharma's lead candidate Lucid-MS for progressive multiple sclerosis earns a 'Buy' rating from Rodman & Renshaw, highlighting its potential ...
Earth Science Tech's acquisition of Zoolzy LLC enhances its compounding pharmacy operations by securing cost-effective APIs and finished FDA-approved ...
Italian pharmaceutical company DuLac Farmaceutici is expanding its U.S. presence by launching its products on OneLavi.com and preparing to meet with m...
VERAXA Biotech has advanced its VXA-222 bispecific antibody-drug conjugate program beyond the discovery phase, marking a key milestone in developing a...
Onco-Innovations has signed a letter of intent to potentially acquire exclusive rights to Ifowonco's oral small-molecule LAG-3 inhibitor, a move that ...
Earth Science Tech's acquisition of Zoolzy LLC aims to enhance its pharmaceutical supply chain and expand into the veterinary market, potentially impr...
SCHOTT Pharma announces that its parent group's updated climate targets, validated by the SBTi, introduce an absolute Scope 3 emissions reduction goal...
Helus Pharma completes enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expected in Q4 2026...
VERAXA Biotech has advanced its VXA-222 bispecific antibody-drug conjugate into the next development stage and expanded its patent portfolio with new ...
Tonix Pharmaceuticals announced FDA feedback supporting its adaptive Phase 2 field study for TNX-4800, a long-acting monoclonal antibody for Lyme dise...
VERAXA Biotech (VRXA) announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, movin...
VERAXA Biotech appoints Christoph Erkel, Ph.D., as chief scientific officer to lead development of its BiTAC platform for cancer therapies targeting s...
NanoViricides secures $3.8 million from a fundamental institutional investor through a registered direct offering, funding ongoing clinical trials for...
VERAXA Biotech AG appointed Christoph Erkel, Ph.D., as chief scientific officer to lead development of its proprietary BiTAC platform technologies for...
VERAXA Biotech AG has received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its development strategy for the lead BiTAC-TCE prog...
VERAXA Biotech announced positive regulatory feedback from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on developme...
Siegfried appoints Eduardo Montanha as COO to combine Drug Substances and Drug Products operations, enhancing integrated end-to-end solutions for phar...
NextPlat Corp's planned acquisition of a rural Florida pharmacy for $1.5 million aims to expand its PharmcoRx footprint into underserved markets, intr...
Onco-Innovations Limited announced the completion of its analytical reference standard preparation program for ONC010, a key step in advancing its lea...
VERAXA Biotech AG has initiated cell line development for its lead BiTAC T-cell engager program through a partnership with ATUM, marking a key step to...
The sustained release polymers market is set to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, as pharmaceutical comp...
VERAXA Biotech reported progress in its BiTAC platform and partnering strategy, with plans to advance lead candidate VXA-102 to IND/CTA readiness by e...
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager program, aiming to improve tumor selectivity and reduce off-tumor tox...
The article highlights that VERAXA Biotech AG, with its next-generation antibody platform for ADCs and T-cell engagers, is well-positioned to benefit ...
Ace Therapeutics announced a full-spectrum preclinical pain research platform offering end-to-end services for analgesic drug development, including d...
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve efficiency and address sustained margin pr...
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for HLP003, a treatment for major depressive disorder, with top...
Voyageur Pharmaceuticals has hired Fluor Corporation for feasibility studies on an iodine extraction facility in Oklahoma and an integrated contrast d...
Knight Therapeutics Inc. has fully repaid its $60 million revolving credit facility drawn to fund the Paladin acquisition, reflecting strong operation...
Voyageur Pharmaceuticals is evaluating three potential U.S. sites for its integrated iodine and barium contrast media manufacturing facility, aiming t...
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emphasizing...
Voyageur Pharmaceuticals has applied for a five-year advanced exploration permit at its Frances Creek barite project, aiming to extract 2,000 tonnes o...
Voyageur Pharmaceuticals closed a $5 million private placement under the Listed Issuer Financing Exemption, with proceeds allocated to FDA licensing f...
Kairos Pharma announced plans to acquire worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor, and provided updates on its oncology...
Quantum BioPharma highlighted its lead drug candidate Lucid-MS for multiple sclerosis and its commercial product unbuzzd(TM) in a BioMedWire podcast, ...
Quantum BioPharma Ltd. is progressing its multiple sclerosis drug Lucid-MS into IND submission stage for Phase 2 trials, offering a novel approach tar...
Redwood AI Corp. announced DTC eligibility for its common shares and engagement of InvestorBrandNetwork for investor awareness services, aiming to enh...
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, is expanding into the U.S. market, as highli...
Sino Biological's new XPressMAX™ kit enables ultra-fast cell-free protein synthesis in 3 hours, supporting AI-driven high-throughput screening for ant...
NanoViricides reported progress in its quarterly filing, highlighting regulatory approval for Phase II trials of NV-387 for MPox in the Democratic Rep...
NanoViricides announced a $2 million registered direct offering with a single institutional investor, providing capital to support its clinical-stage ...
